Tirzepatide for Congenital Generalized Lipodystrophy
New England Journal of Medicine · 13.02.2025 · 392 (7) · 717-719
DOI: 10.1056/nejmc2413871 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 13.02.2025. Verfasst von Svetlana Ten und 2 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 1 Literaturangaben.
Abstract (Originalsprache)
Two patients with congenital generalized lipodystrophy type 1 due to a variant in AGPAT2 (c.589-2A→G) who had been receiving insulin and metreleptin were switched to tirzepatide and were successfully weaned off other therapy.
Autor:innen und Institutionen
- Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
- Children's Hospital of Orange County, Orange, CA.
Zitieren
APA
Ten, S., Bhangoo, A., & Buettner, C. (2025). Tirzepatide for Congenital Generalized Lipodystrophy. New England Journal of Medicine, 392(7), 717-719. https://doi.org/10.1056/nejmc2413871
Vancouver
Ten S, Bhangoo A, Buettner C. Tirzepatide for Congenital Generalized Lipodystrophy. New England Journal of Medicine. 2025;392(7):717-719. doi:10.1056/nejmc2413871
BibTeX
@article{Ten2025,
author = {Ten, Svetlana and Bhangoo, Amrit and Buettner, Christoph},
title = {Tirzepatide for Congenital Generalized Lipodystrophy},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {7},
pages = {717--719},
doi = {10.1056/nejmc2413871}
}
EUVIMED